ATC Group: C09CA Angiotensin II antagonists, plain

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09CA in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09C Angiotensin II antagonists, plain
4 C09CA Angiotensin II antagonists, plain

Group C09CA contents

Code Title
C09CA01 Losartan
C09CA02 Eprosartan
C09CA03 Valsartan
C09CA04 Irbesartan
C09CA05 Tasosartan
C09CA06 Candesartan
C09CA07 Telmisartan
C09CA08 Olmesartan medoxomil
C09CA09 Azilsartan medoxomil
C09CA10

Active ingredients in C09CA

Active Ingredient

Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.

Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.

Eprosartan is a potent, synthetic, orally active non-biphenyl non-tetrazole angiotensin II receptor antagonist, which binds selectively to the AT1 receptor.

Fimasartan, an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound.

Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.

Losartan is a synthetic oral angiotensin-II receptor (type AT1) antagonist. Antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade.

Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.

Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting.

Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1-receptor subtype, which is responsible for the known actions of angiotensin II.

Related product monographs

Document Type Information Source  
 AMIAS Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 APROVEL Tablet MPI, EU: SmPC European Medicines Agency (EU)
 ARBLI Oral suspension MPI, US: SPL/PLR FDA, National Drug Code (US)
 ATACAND Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 AVAPRO Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 BENICAR Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 BLOPRESS Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 CODAVAL Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 COZAAR Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 COZAAR Film-coated tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 COZAAR Powder and solvent for oral suspension MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DIOVAN Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 EDARBI Tablet MPI, EU: SmPC European Medicines Agency (EU)
 IFIRMASTA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 IRPRESTAN Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 LOSAR Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 MICARDIS Tablet MPI, EU: SmPC European Medicines Agency (EU)
 MIZART Tablet MPI, EU: SmPC Pharmaceutical Benefits Scheme (AU)
 OLMETEC Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 OMESAR Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 TELTARTAN Tablet MPI, EU: SmPC Pharmaceutical Benefits Scheme (AU)
 TOLURA Tablet MPI, EU: SmPC European Medicines Agency (EU)
 TROVAL Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 VAPRESS Film-coated tablet MPI, EU: SmPC Web Search
 ZAARIO Film-coated tablet MPI, Generic Health Products Regulatory Authority (ZA)